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ABSTRACT 
This article presents the development of lyophilized dry emulsion tablets prepared with the dry emulsion technique to enhance the in-vitro 
dissolution and in-vivo performance of the poorly bioavailable drug Ezetimibe. Ezetimibe (EZT) is a lipid-lowering drug that inhibits intestinal 
uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble nutrients. Ezetimibe has a very low solubility and 
dissolution rate resulting in highly variable bioavailability, which is also in part due to extensive efflux by p-glycoprotein (P-Gp). Tablets were 
fabricated by freezedrying o/w emulsions of Ezetimibe. The Emulsions were prepared using a matrix former solution (alginate or gelatin, 2 or 
4%) containing a sugar alcohol (mannitol), as the water phase and Labrafac® as the oil phase under proper homogenization. In the present 
study friability, disintegration time, and in-vitro dissolutionof lyophilized dry emulsion tablets were done. Results showed the significant 
influence of the matrix former and emulsifier type on the disintegration time. In-vitro dissolution studies revealed the enhanced dissolution rate 
of Ezetimibe from the lyophilized tablets compared to the plain drug. DSC studies proved presence of the drug in the amorphous form in the 
fabricated tablets. The obtained results suggest a promising, easy-to-manufacture and effective dosage form for the treatment of 
hyperlipidemia. 
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1. INTRODUCTION 
Ezetimibe is an antihyperlipidemic agent capable of lowering 
blood cholesterol levels. It shows one of the most widely 
administered oral statins used in case of elevated plasma 
levels of cholesterol, triglycerides (TG), low-density 
lipoproteins (LDL) in addition to its ability to elevate the 
high-density lipoproteins (HDL). Ezetimibe (EZT) is a lipid-
lowering drug that inhibits intestinal uptake of dietary and 
biliary cholesterol without affecting the absorption of fat-
soluble nutrients. Ezetimibe is classified according to the 
biopharmaceutical classification system (BCS) as a class II 
drug , insoluble  in  aqueous  solutions  of  pH  4 and  below,  
while  being  very  slightly  soluble  in  water and ezetimibe 
shows limited oral bioavailability of about 14% which is 
attributed to its poor aqueous solubility, crystalline nature, 
hepatic first-pass metabolism and mucosal gastrointestinal 
presystemic clearance.  (1-3) 
Hyperlipidemia is abnormally elevated levels of any or all 
lipids or lipoproteins in the blood. It is the most common 
form of dyslipidemia (which includes any abnormal lipid 
levels). (4) 
In this research work, the importance of freeze dried tablet 
for enhancing the solubility of Ezetimibe was explored 
through the formulation of lyophilized dry emulsion tablet 
(LDET). The LDET formulation offers the advantages of both 
emulsions and freeze dried dosage forms. By preparing 
emulsion is efficient in improving dissolution rate and 
bioavailability of the poorly water-soluble drugs. When the 
freeze-dried dosage forms offer, good preservation and 
stability.(5) 
Another specific advantage of freeze-dried formulations as a 
final dry product being a network of solid occupying the 
same volume as the original solution that was initially frozen, 
whereby, a light and porous product readily soluble is 
produced.(6) 
The first component consists of water-soluble polymers, 
such as gelatin, dextrin, alginate and this component 
maintains the shape and provides mechanical strength to the 
tablets. The second component is the disintegration-
enhancing agents, such as sucrose and mannitol, which act 
by cementing the porous framework provided by the water-
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soluble polymer and accelerate the disintegration of 
tablets.(7-8) 
In the present work, gelatin and alginate in combination with 
mannitol were used as the base for the formulation of 
lyophilized dry emulsion tablet. (9) Gelatin, a mixture of 
proteins, is an inexpensive polymer abundantly available in 
nature, can be readily processed into numerous forms and 
shapes. Being biocompatible, biodegradabile, non-toxic and 
non-immunogenic, both sodium alginate and gelatin have 
attracted high consideration and are extensively used in 
various biological applications. The selection of these 
excipients can potentially benefit the formulation in many 
ways. They are expected to form the highly porous matrix 
structure necessary for such dosage form. Also, the structural 
strength was provided by the gelatine whilst the crystallinity, 
hardness and elegance were provided by mannitol. 
Sublimation of water, the process media, induces the porous 
structure during the freeze drying stage. (10-11) 
The purpose of the present work was the development of 
fast disintegrating tablets for Ezetimibe formulated using 
combined emulsion-freeze drying techniques exploring the 
impact of the selected excipients through evaluation of the 
LDET produced, aiming at reducing the disintegration time 
and enhancing the dissolution rate of the drug. 
2. MATERIALS AND METHODS 
Materials: Ezetimibe was kindly donated by Glenmark, 
Mumbai. Labrafac® lipophile WL 1349 (caprylic-capric acid 
triglycerides) was supplied from Fine organics, Mumbai. 
Gelatin, D-Mannitol  and Glycine, Sodium alginate from 
brown algae was provided from Vishal chemicals Mumbai. 
  
Method  
Preparation of lyophilized dry emulsion tablets  
Ezetimibe lyophilized dry emulsion tablets were prepared as 
per Table No. 1 using either gelatin as the matrix former, a 
sugar alcohol (mannitol) and a collapse protectant (glycine). 
The emulsion was first prepared where mannitol and glycine 
were added to a solution of gelatin or alginate containing the 
surfactant, thus forming the aqueous phase. On the other 
hand, the oil phase was composed of 30 mg of Ezetimibe 
solubilized in Labrafac® lipophile WL 1349 (6%). The oil 
phase was then added to the aqueous phase containing 
matrix former, a sugar alcohol and a collapse protectant, 
under homogenization at 15,000 rpm for 5 min.  
Prepared emulsion were then transferred to a freezer at -
22°C and kept for 24 h. The frozen tablets materials were 
placed for 24 h in a Novalyphe-NL 500 Freeze Dryer with a 
condenser temperature of -45°C and a pressure of 7x10-2 for 
3 days. Then the freeze dried composition should be 
compressed into tablets by adding croscarmellose sodium, 
microcrystalline cellulose, and magnesium stearate. 
 
Table 1: Composition of Lyophilized Ezetimibe freeze dried tablet 
Sr. 
No. 
Ingredients F1 F2 F3 F4 F5 F6 
1 Ezetimibe (mg) 10 10 10 10 10 10 
2 Gelatin (%) 3 3.2 3.4 3.6 3.8 4 
3 Sodium alginate(%) 2 1.8 1.6 1.4 1.2 1 
4 Mannitol (%) 0.886 0.886 0.886 0.886 0.886 0.886 
5 Labrafac (%) 6 6 6 6 6 6 
6 MCC (mg) 4 4 4 4 4 4 
7 CCS (mg) 10 10 10 10 10 10 
8 Magnesium Stearate (mg) 5 5 5 5 5 5 
 
3. RESULTS AND DISCUSSION  
Compatibility studies – FTIR: 
The FTIR spectra of the Ezetimibe and physical mixture of 
polymer  were recorded to check interaction between drug 
and polymers. The characteristic peaks of Ezetimibe 
appeared in the spectrum of physical mixture without any 
significant change in the position. It indicates that there was 
no interaction between Ezetimibe and physical mixture of 
polymers. 
 
 
Figure 1: FTIR spectra of Ezetimibe pure drug 
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Figure 2: FTIR spectra of physical mixture 
Differential Scanning Calorimetry (DSC): 
DSC thermograms of pure Ezetimibe and drug excipient 
mixture are shown in Fig.  and Fig.  respectively. Results 
have shown that the sharp exothermic peak was observed of 
the drug individually at 164.20C, corresponding to its 
melting point (1620C -1640C). For the sample containing the 
drug and selected excipient mixture, sharp peak was 
observed of the drug at 164.90C with reduction in peak 
intensity. Thus as there was not a significant shift in 
exothermic peak of drug as that obtained from individual 
drug sample, it can be concluded that there was no 
interaction occurred between the excipient and drug 
Ezetimibe. Thus the Ezetimibe was found to be compatible 
with the selected excipient. 
 
 
Figure 3: Differential Scanning Colorimetry of Ezetimibe Pure Drug. 
 
 
Figure 4: Differential Scanning Colorimetry of Physical Mixture 
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Table 2: Evaluation parameters of tablets 
Formuation  Uniformity of 
weight(%RSD) 
Friability (%) Total ezetimibe 
content (%) 
Disintegration 
time(s) 
F1  0.55±0.17 0.65±0.30 98.06±1.4 158±0.94 
F2  0.45±0.1 0.64±0.27 96.00±1.3 154±1.6 
F3  0.44±0.1 0.63±0.25 97.70±1.3 150±1.88 
F4 0.52±0.17 0.44±0.1 98.34±1.1 150±1.88 
F5 0.42±0.3 0.69±0.06 98.04±1.2 140±1.24 
F6 0.45±0.1 0.42±0.3 97.70±1.3 138±1.6 
The data is presented as (n=3) mean value ±S.D. 
Table 3: Dissolution profile of various batches of tablets in 4.5pH acetate buffer 
Time (min.) % drug release 
F1 F2 F3 F4 F5 F6 
00 00 00 00 00 00 00 
15 5.4 7.65 20.7 7.9 15.3 7.8 
30 17.55 15.3 32.45 18.5 34.7 26.35 
45 25.25 29.3 41.58 47.3 43.8 59.4 
60 42.85 60.9 53.75 74.0 67.7 96.4 
90 56.9 62.4 74.95 77.3 85.85 97.5 
120 64.2 72.75 86.8 89.9 94.95 98.0 
 
 
Figure 6: Dissolution profile of various batches of tablets in 4.5pH acetate buffer. 
Kinetics of Drug Release 
The value of coefficient of regression for different models of different mouth dissolving film formulations is given in Table No. 4 
Table No. 4: Kinetic parameters of Ezetimibe dry emulsion tablets. 
FC Zero 
r2 
First 
r2 
Higuchi 
r2 
Peppas 
r2 
F1 0.9761 0.9895 0.9899 0.9820 
F2 0.9298 0,8984 0.9524 0.9697 
F3 0.9943 0.9898 0.9948 0.9979 
F4 0.9220 0.9759 0.9587 0.9615 
F5 0.9715 0.9899 0.9892 0,9869 
F6 0.8698 0.9115 0.9203 0.9208 
 
 
Figure 7: first order drug release kinetics 
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Figure 8:  Higuchi model 
 
 
Figure 9: Korsmeyer/Peppas model 
 
4. DISCUSSION 
Binding agent is a important aspect in the formulation of 
LDET, because of it increases the hardness of tablets and 
also reduce the surface tension of the drug. In current 
formulation gelatine is used as a binder for freeze dried 
tablet and it acts also matrix former. Other excipients like 
sugar alcohol to produce the porous structure to the 
lyophilised matrix, which positively increase solubility of 
formulation. The porous structure of dosage form which 
leads to difficult to handling, so to influence of freeze dried 
tablets by evaluating the gelatine as a binder or other 
excipients. 
All prepared tablets were acceptable weight variation values 
as indicated by the relative standard deviation (RSD) of the 
tablet mass which ranged from 0.42 to 0.55%. 
Tablet friability was determined by Roche Friabilator and 
weight loss was calculated and presented in terms of % 
friability. From table we can say that percentage weight loss 
of tablets of each formulation was found in the range 0.42 
±0.3 to o.65 ±0.3. It had found that the disintegration time of 
all tablet batches is ranging from 138±1.6 to 158±0.9. 
The total Ezetimibe content was found to be uniform along 
all formulation and ranged from 96±1.3 to 98.34±1.1. In-
vitro dissolution study of the Ezetimibe freeze dried tablet 
show significant percentage drug release in the formulation 
F6, because of higher percentage of gelatine produce the 
hydrophilicity of drug molecule and also reduce surface 
tension of same. 
5. CONCLUSION 
Ezetimibe lyophilized dry emulsion tablets were successfully 
fabricated applying the lyophilization technique using 
Labrafac®, mannitol, glycine and gelatin.The poorly water 
soluble drug Ezetimibe used in the preparation was 
characterized for preformulation and spectral analysis by UV 
spectroscopy and FTIR spectroscopy. The physical 
characteristics and spectra of Ezetimibe were found to be 
identical with standard given in analytical profile of drug 
substance. Polymer and drug were checked for compatibility 
by FTIR and DSC. It was evident that there was no probable 
unnecessary interaction found between drug and polymer. 
Preferable tablet properties were obtained regarding 
friability and uniformity of weight in addition to enhanced 
drug release properties and excellent disintegration 
characteristics which are showed in formulation F6.  
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